Allogene Therapeutics, Inc. Logo

Allogene Therapeutics, Inc.

Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.

ALLO | US

Overview

Corporate Details

ISIN(s):
US0197701065
LEI:
Country:
United States of America
Address:
210 EAST GRAND AVENUE, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies. The company's 'off-the-shelf' product platform utilizes T-cells from healthy donors to create readily available treatments designed to be more accessible, scalable, and reliable than patient-specific autologous therapies. Its clinical pipeline targets hematologic malignancies (blood cancers), solid tumors, and autoimmune diseases. Key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL), ALLO-316 for renal cell carcinoma (ccRCC), and ALLO-329 for autoimmune diseases. Allogene leverages multiplex gene-engineering and gene-editing capabilities to develop its product candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allogene Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allogene Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Allogene Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SAMJIN PHARMACEUTICAL CO.,LTD Logo
Researches & develops drugs for cardiovascular, respiratory, and gastrointestinal disorders.
South Korea
005500
SAMSUNG BIOLOGICS CO.,LTD. Logo
A CDMO providing end-to-end development and manufacturing services for the biopharma industry.
South Korea
207940
Sana Biotechnology, Inc. Logo
Engineering cells as medicine to repair genes and treat cancer, diabetes, and autoimmune disorders.
United States of America
SANA
SanBio Company Limited Logo
Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.
Japan
4592
SANGAMO THERAPEUTICS, INC Logo
Developing genomic cures for severe genetic diseases using proprietary zinc finger technology.
United States of America
SGMO
SANIGEN Co., Ltd. Logo
Provides food safety solutions and genetic diagnostics for the entire food industry.
South Korea
188260
Sanofi Logo
A global biopharma firm researching and developing innovative medicines and vaccines for the world.
United States of America
SNY
Sanofi Logo
Global biopharma firm researching, developing & marketing prescription medicines & vaccines.
France
SAN
SANTEN PHARMACEUTICAL CO.,LTD. Logo
A global ophthalmology specialist developing drugs and devices for glaucoma, dry eye, and infections.
Japan
4536
Santhera Pharmaceuticals Holding AG Logo
Develops innovative medicines for rare neuromuscular and mitochondrial disorders.
Switzerland
SANN

Talk to a Data Expert

Have a question? We'll get back to you promptly.